Zobrazeno 1 - 10
of 44
pro vyhledávání: '"E. J. Heathcote"'
Publikováno v:
Histopathology. 61:473-487
AIMS: A fall in hepatic fibrosis stage may be observed in patients with chronic hepatitis C (CHC); however, parenchymal architectural changes may also signify hepatic remodelling associated with fibrosis regression. The aim of this study was to utili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d40fdae661f15714981cfe973de43509
https://doi.org/10.1111/j.1365-2559.2012.04249.x
https://doi.org/10.1111/j.1365-2559.2012.04249.x
Publikováno v:
Journal of Hepatology. 55(2):466-473
Genotypes 2 and 3 (G2/G3) of hepatitis C virus have been lumped together as 'easy to treat'. As a result, guidelines recommend 24 weeks of peginterferon/ribavirin for both. However, a closer look at trials shows that these genotypes are not the same,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1c8aeaa68c1c3c390b2362f1117e948
Publikováno v:
Journal of Viral Hepatitis. 17:834-838
Summary. Aim: Elevated body mass index (BMI) in chronic hepatitis C (CHC) has been associated with reduced rates of sustained virological response (SVR). The aims of this study were to determine whether early viral kinetics (and subsequently SVR) are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab2fe8f955618f9e42445fc594736df5
https://doi.org/10.1111/j.1365-2893.2010.01248.x
https://doi.org/10.1111/j.1365-2893.2010.01248.x
Publikováno v:
Journal of Viral Hepatitis. 16:802-813
Accurate prognostic estimates were required to ensure the sufficiency of the $1.1 billion compensation fund established in 1998 to compensate Canadians who acquired hepatitis C virus (HCV) infection through blood transfusion between 1986 and 1990. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52e83354d7939621314e227e80914e9e
https://doi.org/10.1111/j.1365-2893.2009.01136.x
https://doi.org/10.1111/j.1365-2893.2009.01136.x
Autor:
G. Y. Minuk, S. S. Lee, E. Lentz, Mitchell L. Shiffman, Sugantha Govindarajan, Paul J. Pockros, Robert Reindollar, Luis A. Balart, E. J. Heathcote, Gregory T. Everson
Publikováno v:
Alimentary Pharmacology & Therapeutics. 27:542-551
Summary Background Patients with chronic hepatitis C virus and advanced fibrosis or cirrhosis are at risk for disease progression and hepatic decompensation. Aim To determine the effects on hepatic histology of treatment with peginterferon alfa-2a (9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7f67849f1d1b86e98a0b8b88cb95115
https://doi.org/10.1111/j.1365-2036.2008.03620.x
https://doi.org/10.1111/j.1365-2036.2008.03620.x
Autor:
Jordan J. Feld, E. J. Heathcote
Publikováno v:
Seminars in Liver Disease. 26:116-129
The natural history of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B is very heterogeneous. Age at acquisition is a major factor in determining the natural history of chronic infection. The vigor of the host immune response to the virus,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2172d1751bc7fbf8bcbed6c52d3e430b
https://doi.org/10.1055/s-2006-939750
https://doi.org/10.1055/s-2006-939750
Autor:
W. G. E. Cooksley, A. Lin, Mitchell L. Shiffman, E. J. Heathcote, J. de Pamphilis, Joseph Hoffman, Sam Lee, L. Balart, Geoffrey Dusheiko, Rajender Reddy, Teresa L. Wright, Robert Reindollar
Publikováno v:
New England Journal of Medicine. 343:1673-1680
Background Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to treat. In patients with chronic hepatitis C but without cirrhosis, once-weekly administration of interferon modified by the attachment of a 40-kd branched
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::303697ce05e86734e5edcdf43044b6bd
https://doi.org/10.1056/nejm200012073432302
https://doi.org/10.1056/nejm200012073432302
Publikováno v:
American Journal of Gastroenterology. 94:47-53
To document the natural history of asymptomatic primary biliary cirrhosis and identify prognostic features that would predict the development of symptomatic disease.A retrospective chart review of all patients with abnormal liver biochemical tests an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c51ba6936036e0f716a0a594f4a6eb
https://doi.org/10.1111/j.1572-0241.1999.00770.x
https://doi.org/10.1111/j.1572-0241.1999.00770.x
Publikováno v:
Scopus-Elsevier
Background—Fatigue is a frequent and debilitating symptom in patients with primary biliary cirrhosis (PBC).Aims—To study fatigue in relation to sleep, depression, and liver disease severity.Methods—Patients with PBC completed validated self rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d5633547586d59f85af2e71faaed95
https://doi.org/10.1136/gut.43.5.705
https://doi.org/10.1136/gut.43.5.705
Autor:
E J, Heathcote
Publikováno v:
Clinics in Liver Disease. 2:303-311
Autoimmune cholangitis is the term that has been used to describe patients who have the clinical, biochemical, and histologic characteristics of primary biliary cirrhosis (PBC), but who are antinuclear antibody positive rather than anti-mitochondrial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f06acbf7c3843e5d1eba31ea29807637
https://doi.org/10.1016/s1089-3261(05)70009-x
https://doi.org/10.1016/s1089-3261(05)70009-x